Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

NCT00849875 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00849875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00849875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
May 26, 2009
Completion date
November 17, 2014
Enrollment
48 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma